e-learning
resources
ERJ
2017
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Licence to kill senescent cells in idiopathic pulmonary fibrosis?
Arnaud A. Mailleux, Bruno Crestani
Source:
Eur Respir J, 50 (2) 1701360; 10.1183/13993003.01360-2017
Journal Issue:
August
Disease area:
Interstitial lung diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Arnaud A. Mailleux, Bruno Crestani. Licence to kill senescent cells in idiopathic pulmonary fibrosis?. Eur Respir J, 50 (2) 1701360; 10.1183/13993003.01360-2017
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Muscle energy techniques for COPD patients: Effects on pulmonary function and activities of daily living
Related content which might interest you:
Does apoptosis evasion only affect fibroblasts from idiopathic pulmonary fibrosis?
Source: Annual Congress 2013 –Cell signalling and inflammation: what's new in 2013?
Year: 2013
Role of dendritic cells in pulmonary fibrosis in mice
Source: International Congress 2016 – ILD: from the bench to the bedside
Year: 2016
Circulating monocytes from interstitial lung disease patients show an activated phenotype
Source: International Congress 2016 – ILD: from the bench to the bedside
Year: 2016
Tryptase+ mast cells associate with fibrotic regions in the lungs of idiopathic pulmonary fibrosis patients; a multiplex staining approach
Source: International Congress 2016 – How the understanding og molecular and genomic crosstalk is helping to diagnose lung disease
Year: 2016
Apoptosis in epithelial cells in patients with idiopathic pulmonary fibrosis
Source: Eur Respir J 2004; 24: Suppl. 48, 481s
Year: 2004
Effect of nintedanib, pirfenidone, N-acetylcysteine and their combinations on cultured myofibroblast-type cells derived from patients with asbestosis and idiopathic pulmonary fibrosis
Source: International Congress 2015 – Airway remodelling: recent developments
Year: 2015
Club cell secretory protein-CC16 is increased in idiopathic pulmonary fibrosis
Source: International Congress 2016 – ILD pathogenesis
Year: 2016
Proliferating SPP1/MERTK-expressing macrophages in idiopathic pulmonary fibrosis
Source: Eur Respir J, 54 (2) 1802441; 10.1183/13993003.02441-2018
Year: 2019
Human airway trypsin-like protease: Friend or foe in idiopathic pulmonary fibrosis?
Source: International Congress 2016 – Common mechanisms in lung development and fibrosis
Year: 2016
Modulation of lung CD11c+ dendritic cells by TGF-β in pulmonary fibrosis in mice
Source: International Congress 2016 – Translational studies in lung disease
Year: 2016
Immunologically 'supercharged' monocytes as drivers of chronic fibrosis in idiopathic pulmonary fibrosis
Source: Virtual Congress 2020 – Prognosis and biomarkers of idiopathic pulmonary fibrosis
Year: 2020
Loss of PTEN induced lung fibroblasts exhibiting similar pathogenic features to cancer cells in idiopathic pulmonary fibrosis
Source: International Congress 2014 – ILDs 2
Year: 2014
Quality of life of patients with idiopathic pulmonary fibrosis (IPF) - What can the Australian IPF registry tell us?
Source: International Congress 2015 – IPF: clinical aspects II
Year: 2015
Alveolar type II cells transplantation decrease fibrocyte migration in pulmonary fibrosis
Source: Annual Congress 2013 –Novel mechanisms in lung injury
Year: 2013
Anti-fibrotic effects of pirfenidone in lung fibroblasts derived from patients with idiopathic pulmonary fibrosis
Source: International Congress 2015 – IPF: from bench to bedside
Year: 2015
The immunomodulatory effect of protein S in pulmonary fibrosis
Source: Annual Congress 2013 –Diffuse pulmonary fibrosis
Year: 2013
Anti-parietal cell autoimmunity in IPF patients
Source: International Congress 2016 – IPF: from pathogenesis to treatment I
Year: 2016
Fibrocytes are a potential source of fibroblasts in idiopathic pulmonary fibrosis
Source: Eur Respir J 2007; 30: Suppl. 51, 719s
Year: 2007
Effect of pirfenidone on TGF-beta-induced pro-fibrotic effects in primary human lung cells derived from patients with idiopathic pulmonary fibrosis
Source: International Congress 2014 – ILDs 2
Year: 2014
LSC - 2020 - Characterizing lung resident mesenchymal stem cells in idiopathic pulmonary fibrosis patients
Source: Virtual Congress 2020 – Idiopathic pulmonary fibrosis and interstitial lung disease: progression, genes and more
Year: 2020
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept